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The matrix metalloproteinases MMP9 and MMP13 catalyze the degradation of extracellular matrix (ECM) components in the growth
plate and at the same time cleave and release biologically active molecules stored in the ECM, such as VEGFA. In mice, ablation of
Mmp9,Mmp13, or bothMmp9 andMmp13 causes severe distortion of the metaphyseal growth plate. We report that mutations in either
MMP9 orMMP13 are responsible for the human disease metaphyseal anadysplasia (MAD), a heterogeneous group of disorders for which
a milder recessive variant and a more severe dominant variant are known. We found that recessive MAD is caused by homozygous loss
of function of either MMP9 or MMP13, whereas dominant MAD is associated with missense mutations in the prodomain of MMP13
that determine autoactivation of MMP13 and intracellular degradation of both MMP13 and MMP9, resulting in a double enzymatic
deﬁciency.Introduction
Different families of proteases mediate ECM turnover and
cartilage remodelling in the growth plate, in particular
ADAM-TSs, cathepsins, and matrix metalloproteinases
(MMPs).1,2 These enzyme families are known to differ in
expression pattern and substrate speciﬁcity, but their func-
tion in the growth plate remains poorly deﬁned. Classiﬁed
by homologous functional domains and common activa-
tion mechanisms, the MMP family currently comprises
23 ECM-degrading endopeptidases in the human.3 Many
MMPs are able to cleave the most abundant proteoglycans
and collagens of skeletal tissues in vitro; therefore, they are
presumed to play important roles in bone formation and
growth. However, mice with targeted ablation of Mmp
genes are, with few exceptions, viable and show only a
mild or no skeletal phenotype.2 The expression patterns
of MMP9 (MIM *120361) and MMP13 (MIM *600108) at
the chondro-osseous junction within the human growth
plate show only partial overlap.4 MMP9 is predominantly
secreted by chondroclasts, osteoclasts, and endothelial
cells, whereas MMP13 is produced by hypertrophic chon-
drocytes and osteoblasts. Nevertheless, loss of either
Mmp9 or Mmp13 causes similar alterations of growth plate
architecture in mice. The hypertrophic zone of these
animals is markedly expanded as a result of reduced ECM
remodelling, prolonged chondrocyte survival, and delayed
vascular invasion.5–7 Mmp9 synergizes withMmp13 in the
coordinated decomposition of cartilage matrix, as indi-
cated by a more severe phenotype in double-null mice.6
On the basis of these observations, ECM remodelling by168 The American Journal of Human Genetics 85, 168–178, August 1the two enzymes is proposed to be a rate-limiting process
in normal skeletal morphogenesis. Remarkably however,
the skeletal changes in the knockoutmice are only apparent
during the growth phase, as even the more pronounced
phenotype of a combined inactivation of Mmp9 and
Mmp13 resolves spontaneously when longitudinal bone
growth ceases.7
Most of the phenotypic features described in Mmp9 and
Mmp13 knockout mice mimic the clinical picture of meta-
physeal anadysplasia (MAD [MIM 309645]), a human skel-
etal dysplasia characterized by severe skeletal changes that,
in contrast with the progressive course of most other skel-
etal dysplasias, resolve spontaneously with age (Figures
1A–1D). Patients attain a normal stature in adolescence
and show improvement or complete resolution of varus
deformity of the legs and rhizomelic micromelia.8 Inheri-
tance of MAD is controversial in the sense that a single
but different mode of transmission was claimed to be
applicable; in particular, X-linked recessive, autosomal-
recessive, and autosomal-dominant transmission have all
been proposed.8–12 The presented data resolve this contro-
versy, adding MAD to the list of disorders with more than
one pattern of inheritance and a variety of disease mecha-
nisms.
We identiﬁedmutations inMMP9 andMMP13 as themo-
lecular basis of MAD. Loss of function of either MMP9 or
MMP13 is associated with recessive disease, whereas domi-
nant missense mutations in the prodomain of MMP13
cause intracellular autocatalysis, similar to the effect of
a single amino acid substitution described in spondyloepi-
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602111]), another skeletal dysplasia with dominant in-
heritance.13,14 Key clinical and radiographic features of
SEMDMO and MAD are highly similar;
13 accordingly, acti-
vating MMP13 prodomain mutations found in both disor-
ders have the same consequences at the molecular level.14
The dominant effect of autoactivated proMMP13 was
resolved by the observation that both mutant and wild-
type proteins are degraded in the endoplasmatic retic-
ulum.14 Our results conﬁrm these ﬁndings and provide
evidence that the transcatalytic mechanism also targets
proMMP9, explaining themore severe phenotype of domi-
nant disease by double enzymatic deﬁciency. Furthermore,
our data indicate a functional link between MMP13 and
MMP9 in endochondral ossiﬁcation, as impaired MMP9
protein function, caused by direct inactivation (in recessive
disease due toMMP9 loss of function), impaired activation
(in recessive disease due to MMP13 loss of function), or
transcatalytic degradation (in dominant disease caused by
MMP13 gain of function) appears to be a common down-
stream step in the pathogenesis of MAD.
Subjects and Methods
Subjects
All subjects were ascertained by physician-initiated referral. We
collected blood and isolated DNA from cases diagnosed at the
Children’s Hospital of Mainz and Freiburg University under
a protocol approved by the ethics review board Rheinland-Pfalz,
or from cases referred through the ESDN (European Skeletal
Dysplasia Network) and SKELNET (German Skeletal Dysplasia
Network). Informed consent was obtained for all subjects. Each
family member was assessed by clinical and radiographic criteria.
Control samples and primary cells were obtained from ancestry-,
sex-, and age-matched healthy individuals.
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Figure 1. Clinical and Radiographic
Presentation of MAD
(A and B) Patient 1 (index patient IV.2 of
family A) at the age of (A) 2 yrs, 3 mo
and (B) 4 yrs, 3 mo. Radiographs demon-
strate spontaneously regressive metaphy-
seal irregularities (arrows) of radius, ulna,
tibia, and femur; the spine is normal.
(C) The growth curve of patient 1 (red line)
shows a transient growth deceleration
maximal in the second year of life.
(D) Genua vara and metaphyseal fraying in
dominant (patient 5, index patient IV.2 of
family B at the age of 1 yr, 8 mo) and reces-
sive (patient 12, index patient II.2 of
family E in Figure 2B at the age of 1 yr,
1 mo) MAD are indistinguishable. Patient
numbers refer to Table 1 and Figure 2.
Genomic Analysis and Mutation
Detection
The exons including intron-exon bound-
aries of MMP9 and MMP13 were ampliﬁed
by polymerase chain reaction (PCR) via
standard protocols with primers listed in
Table S1 or ones that had been published previously.14 Sequences
of ampliﬁed PCR products were determined on an ABI3100 capil-
lary sequencer (Applied Biosystems). Sequence datawere processed
with ABI software and analyzed with Sequencher (Genecodes).
We compared amplicon sequences against the cDNA reference
sequence forMMP9 andMMP13, with nucleotide numbering start-
ing from the ﬁrst transcribed nucleotide of the reference sequence.
Mutations and polymorphisms were conﬁrmed in two indepen-
dently ampliﬁed PCR products via bidirectional sequencing.
Allele-Frequency Analysis
In 114 normal controls of European descent, exon 2 ofMMP13was
ampliﬁed and sequenced unidirectionally to screen for dominant-
MAD-associated mutations. For MMP13 c.300T>C, detected in
families B and C, the sequence change falls within a BspHI restric-
tion endonuclease cleavage site, ablating the recognition sequence
in the mutant allele. PCR products of exon 2, derived from 114
normal controls of Japanese and Korean descent, were cleaved
with BspHI (New England Biolabs). Only cleavage products of
222 bp and 207 bp, expected for wild-type MMP13, were seen in
controls; affected individuals showed one uncleaved PCR product
of 429 bp in addition. Restriction analysis for the recessive-MAD-
associated sequence change in MMP13 was done by digesting the
PCRproduct of exon5withBslI (MBI Fermentas). Controls showed
only uncleaved wild-type alleles at 379 bp; patients showed two
bands at 162 bp and 217 bp, resulting from a new recognition
sequence introduced by the homozygous c.722C>A mutation in
family D. Exon 1 of MMP9 was analyzed by restriction with NlaIII
(New England Biolabs). PCR products from individuals affected
by the homozygous c.21T>A mutation lack the recognition site
and show a single band at 293 bp, whereas only the cleavage prod-
ucts at 102 bp and 191 bp were detected in unaffected controls.
RNA Extraction and Quantitative Real-Time PCR
Total RNA from ﬁbroblasts and cell lines was extracted with Trizol
(Invitrogen), followed by DNaseI treatment (Roche) and columnThe American Journal of Human Genetics 85, 168–178, August 14, 2009 169
puriﬁcation (QIAGEN). cDNAwas synthesized from 1 mg total RNA
with Superscript III reverse transcriptase (Invitrogen) and oligo
dT16 primers. Quantitative PCR was performed on an ABI 7300
Real-TimePCRSystem(AppliedBiosystems).DeltaCt relativequan-
tiﬁcation, PCR efﬁciency correction, and multiple reference gene
normalization (UBC, HMBS, PDHA) were calculated with qBase.15
Cellular Transformation and Expression of MMP9
and MMP13 cDNAs
HEK293T human embryonic kidney cells, NIH 3T3, and primary
ﬁbroblasts derived from skin biopsies (after the second passage)
were grown in Dulbecco’s modiﬁed Eagle’s medium (DMEM) sup-
plemented with 10% FBS, 2 mM L-glutamine, 2 U/ml penicillin,
and 2 mg/ml streptomycin in a humidity-controlled incubator at
37C with 5% CO2. Full-length MMP9 and MMP13 cDNAs were
generated by PCR with the use of Pfu proofreading polymerase
(Stratagene) with cDNA from normal human ﬁbroblasts as
template and were inserted into pCRII-TOPO (Invitrogen).
Sequence-veriﬁed inserts were subcloned into pcDNA3.1 and into
pcDNA3.1V5-HIS-TOPO (Invitrogen). We introduced mutations
inMMP13 by PCR-mediated site-directedmutagenesis as described
previously.16 The nucleotide sequences of the mutants were veri-
ﬁed by sequence analysis of the complete corresponding cDNAs.
Minigene constructs were generated by subcloning PCR products
of the MMP9 promoter, including exon 1, into pUC19, with the
SapI site in exon 1 used to generate a completeMMP9 open reading
frame fused to the endogenous 50-regulatory region. The MMP9
c.21T>A mutation was introduced by using DNA of patient 12 as
template in the PCR, and wild-type constructs were generated
with DNA from unaffected controls. Blunt-ended fragments of
Minigene_1 (includingMMP9 cDNA and 1623 bp upstream of the
transcriptional start) and Minigene_2 (including MMP9 cDNA
and 741 bp upstream of the transcriptional start) replaced the
CAG promoter in the HincII-EcoRV-digested pCAGIG17 vector,
which allows detection of transfected cells on the basis of their
green ﬂuorescence when illuminated at 478 nm. Expression
constructs were transiently transfected with the use of FuGENE6
(Roche) and a standard calcium phosphate protocol.18 Cells and
supernatants were harvested 48 hr after transfection; prior to
RNA and protein extraction, cells were washed with PBS. Lysates
were prepared by incubation in 1 ml lysis buffer (20 mM Tris-HCl,
pH 8, 137 mM NaCl, 10% glycerol, 1 mM NaF, 1 mM Na3VO4,
0.1% NP-40) plus complete protease inhibitor (Roche) for 20 min
on ice, followed by centrifugation at 14,000 3 g and at 4C for
10 min. For the analysis of secreted MMP proteins, the medium
was changed to serum-free Optimem I (Invitrogen) 24 hr prior to
collection, conditioned supernatants concentrated by centricon
Plus-20 columns (Millipore). Total protein concentration in lysates
and supernatants was determined by the Bradford microassay
procedure (Bio-Rad), equal protein amounts (50–100 mg) precipi-
tated by acetone, fractionated by SDS-PAGE, and transferred to
nitrocellulose membranes (GE Healthcare). Immunoblots were
probed with antibodies against human MMP13 (MAB13424 and
AB8114, Millipore), human MMP9 (MAB3309, Millipore), the V5
(V8012, Sigma) and HIS (11922416001, Roche) epitope tags, and
b-actin (AV40173, Sigma). Appropriate secondary antibodies
(Dako) were used for visualization with enhanced chemilumines-
cence (GE Healthcare).
Concentration and Activity of MMP9 and MMP13
Concentration of MMP9 and MMP13 was measured in plasma
(NH4-heparinate) collected under standardized conditions, serum,170 The American Journal of Human Genetics 85, 168–178, August 1and conditioned supernatants via a ﬂurorogenic substrate acti-
vity assay (Fluorokine E, R&D). MMP proteins were speciﬁcally
captured in an antibody-coated microtiter plate from 100-fold
diluted samples. Wells were washed four times, then activated
with 1 mM of p-aminophenylmercuric acetate (APMA) and incu-
bated for 20 hr in the dark at 37C. MMP actitviy was detected
by exciting the cleaved ﬂurorogenic peptide substrate ES001 at
320 nm and reading the emission at 405 nm, endpoint mode
(Mithras Multimode reader, Berthold). The concentrations of
MMPs were extrapolated from standard curves generated with
recombinant human MMP9 and MMP13 (R&D). Collagenase
activity in conditioned supernatants was quantiﬁed with ﬂuores-
cently labeled native type II collagen (Millipore) and gelatin
(Molecular Probes). For ﬁbrillar type II collagen, diluted samples
were activated with 1 mM APMA for 1 hr, then incubated with
the substrate for 2 hr at 35C in the dark, before the ﬂuorescence
extracted from degradation products was excited at 490 nm and
measured at 520 nm. Degradation of gelatin was measured after
activation of diluted samples for 16 hr with 1mMAPMA and incu-
bation for 2 hr at ambient temperature in the dark. Kinetic deter-
mination of ﬂuorescence intensity was used in calculating speciﬁc
activity, given that collagenase activity is directly proportional
to the intensity of ﬂuorescence generated by the cleavage of sub-
strates. Units were deﬁned as cleaved mg of collagen per minute.
Total protein concentration of whole-cell lysates and conditioned
supernatants was measured by the Bradford microassay procedure
(Bio-Rad). Speciﬁc collagenolytic activity (U per mg protein) of the
samples was determined by the ratio of total collagenase units and
total protein content.
Protein Structure Modeling
The atomic coordinates of the X-ray crystal structure and NMR
structure of MMP13 domains19 and a model of proMMP13 were
obtained from the Protein Data Bank (PDB 1UC1, 1FM1, 1XUC);
a prodomain model was based on the structures of proMMP1
(PDB 1SU1), proMMP2 (PDB 1CK7), and proMMP3 (PDB 1SLM)
with the use of the semi-automated modeling server SWISS-
MODEL20 as described previously.14 Figures were created with
MBT21 and the molecular graphics program PyMOL.
Statistics
We tested signiﬁcance between individual groups by using the
two-tailed unpaired Student’s t test (p < 0.05). Data are expressed
as the mean5 SDM.
Results
We investigated themolecular basis ofMAD in ﬁve families
(Table 1). All patients fulﬁlled the minimal clinical diag-
nostic criteria of MAD, namely normal length at birth
and transitory bowing of the legs. In dominant disease,
bowing and rhizomelic shortening was coincident with
growth deceleration in the second year of life. Height drop-
ped to a range of 1 SD to 4 SD; signiﬁcant catch-up
growth and spontaneous regression of bow legs in late
childhood was noted (Figures 1A–1C). Radiographic exam-
ination demonstrated extensive metaphyseal widening
and fraying in all cases (Figures 1A, 1B, and 1D). Follow-
up examination documented spontaneous regression and4, 2009
Table 1. Summary of Clinical and Molecular Findings in MAD Patients
Patient
Age at
Ascertain-
ment Sex
Family,
Individual Inheritance Mutation Origin
Maximum Growth
Deceleration
in the 2nd Yr
of Life
Stature at
Specified
Age
Bowed
Legs in
Infancy
Micro-
melia
Laboratory
Parameters
1 2y6m F A, IV.2 dominant MMP13 p.F55S Germany 3.89 SD 6y, 2.35 SD severe yes normal
2 39y F A, III.2 dominant MMP13 p.F55S Germany 3.17 SD 39y, 1.72 SD severe yes normal
3 65y F A, II.4 dominant MMP13 p.F55S Germany n. d. 65y, 2.58 SD severe,
persistent
yes normal
4 15y M B, IV.2 dominant MMP13 p.M72T Germany 2.29 SD 18y, þ1.60 SD yes yes normal
5 12y F B, IV.3 dominant MMP13 p.M72T Germany 2.51 SD 15y, 0.89 SD yes yes normal
6 42y M B, III.3 dominant MMP13 p.M72T Germany n. d. 42y, þ1.2 SD yes yes normal
7a 62y M B, II.1 dominant MMP13 p.M72T Germany n. d. 62y, þ0.72 SD yes yes n. d.
8 3y F C, II.1 dominant MMP13 p.M72T Japan 2.9 SD 6y, 2.89 yes yes normal
9 4m F C, II.2 dominant MMP13 p.M72T Japan 2.78 SD 3y1m, 1.54 SD yes yes normal
10 28y F C, I.2 dominant MMP13 p.M72T Japan n. d. 32y, 1.9 SD yes yes normal
11 4m M D, II.1 recessive MMP13 p.H213N Morocco 1.35 SD 3y2m, 1.0 SD yes mild normal
12 14m F E, II.1 recessive MMP9 p.M1K Pakistan þ0.23 SD 7y, 0.23 SD yes no normal
13 2y M E, II.2 recessive MMP9 p.M1K Pakistan 0.15 SD 5y, 0.77 SD yes no normal
Abbreviations are as follows: F, female; M, male; n.d., not determined; y, year; m, month; SD, standard deviation.
a Patient 7 was deceased at the time of ascertainment; mutation analysis was performed with DNA extracted from archival pathologic specimen. Laboratory
parameters included calcium, phosphate, alkaline phosphatase, vitamin D, and intact parathyroid hormone.disappearance of the metaphyseal alterations over several
years. Pedigrees of unrelated families of diverse ethnic
origin suggested two genetically distinct forms of MAD:
the clinically more severe type with reduced stature
(MAD type 1; Spranger type) shows autosomal-dominant
inheritance over several generations in three kindreds
(Figure 2A), whereas the milder type with normal stature
(MAD type 2; Maroteaux type), observed in consanguin-
eous families, is inherited as an autosomal-recessive trait
(Figure 2B). The radiographic presentation of both types
was indistinguishable; no discriminating feature could be
deﬁned on the basis of our collective observations and
previous reports8–12 (Figure 1D).
The similarity between mouse MMP knockouts and
human MAD prompted us to consider MMP9 and MMP13
as possible candidates. Analysis of both genes by direct
sequencing of genomic DNA demonstrated heterozygous
single-nucleotide exchanges within exon 2 of MMP13 in
all patients affected by dominant MAD, whereas MMP9
sequence was normal in coding and regulatory regions.
The changes inMMP13 segregated with the disease pheno-
type in familial cases and were not present among 228
alleles of ancestry-matched unaffected individuals. In
family A, a c.249T>C transition predicted a single amino
acid substitution, p.F55S, in the prodomain of MMP13
(Figure S1). In proximity to the ﬁrst sequence change,
a c.T300>C transition results in the amino acid substitu-
tion p.M72T that is also located in the prodomain of
MMP13 (Figure S1). This most prevalent mutation was
detected in all affected individuals of families B and C.The AmerDisease-associated sequence changes in dominant MAD
are in the same highly conserved domain as p.F56S (Fig-
ure S2), a missense mutation in proMMP13 reported as
the cause of SEMDMO in a single large kindred.
13,14 Thus,
both diseases are allelic and may represent a clinical spec-
trum.
Recessive MAD proved to be genetically heterogeneous,
as we identiﬁed homozygous sequence changes in either
in MMP13 or MMP9. In family D, a c.722C>A transition
in exon 5 of MMP13 changes the highly conserved histi-
dine 213 of the catalytic domain to asparagine in the pre-
dicted open reading frame of proMMP13 (Figure S3). In the
second recessive kindred, family E, MMP13 was normal,
but a c.21T>A transversion in exon 1 altered the start
codon of proMMP9, substituting methionine with lysine
(Figure S4). As the next AUG providing a putative aberrant
initiation site in the mRNA sequence is located 177 nucle-
otides downstream, the mutation is likely to ablate transla-
tion of a functional proMMP9 protein. In both families,
homozygous mutations segregated with the MAD pheno-
type, while the parents were heterozygous and the unaf-
fected sibs were heterozygous or homozygous wild-type;
the mutations were not seen in 228 alleles of unaffected
controls.
To elucidate the effect of MAD-associated mutations on
MMP protein level and function, we quantiﬁed both
proteins in patients’ plasma and cells by immunoblot
and collagenolytic activity. Circulating MMP13 activity
in patients with dominant MAD was barely detectable
(Figure 3A). Immunoblot analysis of extracts from culturedican Journal of Human Genetics 85, 168–178, August 14, 2009 171
AB
Figure 2. Pedigrees of MAD Families
Abridged pedigrees of familes with (A) dominant and (B) recessive MAD are shown. Numbers of individuals correspond to Table 1;
numbers in parentheses indicate individuals from whom no DNAwas available. Symbol notations are as follows: squares, males; circles,
females; open symbols, unaffected individuals; ﬁlled symbols, affected mutation carrier of the nucleotide and predicted amino acid
change indicated on top; hatched symbols, likely affected individuals. Symbols with a slash through them indicate deceased individuals.
Index patients are marked with a red arrow.normal ﬁbroblasts revealed a band at the size expected for
proMMP13, but this band was absent in the patient’s cell
samples (Figure 3C). We then transfected wild-type and
mutagenized expression constructs of human MMP13
cDNA in HEK cells and compared secreted MMPs in condi-
tioned supernatants. The catalytic domain of MMPs con-
tains within the sequence HExxHxxGxxH three conserved
histidines that ligate the active site Zn2þ (Figure 4A and
Figure S3). The glutamate residue of the catalyticmotif acti-
vates a zinc-bound H2O molecule, providing the nucleo-
phile that cleaves peptide bonds.3 The recessive-MAD-
associated MMP13 mutation, p.H213N, substitutes the
third histidine of the consensus sequence with asparagine,
thus preventing zinc ion ligation and correct conformation
of the catalytic core. Accordingly, secretion and protein
stability were not affected, but the secreted protein had
no detectable collagenolytic activity (Figures 4B and 4C).
In family E bearing the homozygous MMP9 mutation,
MMP13 levels in plasmawere normal, butMMP9 reactivity
was absent as anticipated (Figure 3D). Given that heterozy-
gous carriers also showed a reduced concentration (Fig-
ure 3D), we concluded that the p.M1K start codon muta-
tion abolished translation and that this effect was not
compensated for by aberrant initiation at a non-AUG or
AUG encoded in the mRNA. The analysis of minigene
constructs comparing the expression levels of wild-type
andmutant humanMMP9 under the control of two endog-172 The American Journal of Human Genetics 85, 168–178, Augustenous promoter fragments fully supported these conclu-
sions (Figure 3E).
Although the molecular pathology of recessive MAD
disease could thus be attributed to impaired synthesis of
MMP9 protein or synthesis of catalytically inactive
MMP13, an explanation for the drastic decrease of MMP13
levels observed in dominant MAD was less evident.
Surprisingly, not only MMP13, but also MMP9, was signif-
icantly reduced in the plasma of these patients in spite of
normal genomic MMP9 sequences (Figure 3B). For the
MMP13 p.F55S mutation, MMP9 reduction was more
pronounced in immunoblot analysis of skin ﬁbroblasts
(Figure 3C). The prodomains of diverse proteases serve
as autoinhibitory intramolecular chaperones to prevent
activation during synthesis and protein folding;22–24
therefore, prodomain mutations may cause autoactiva-
tion.14,25,26 To test for possible autocatalytic activation of
proMMP13 in MAD, we compared protein stability and
enzymatic activity of all pathogenic missense proMMP13
mutants. A strong reduction of intact proMMP13 was
evident in immunoblot analysis of conditioned medium
or cell lysates from HEK cells transfected with constructs
bearing disease-associated mutations (Figures 4A–4C).
The degree of destabilization conferred by the different
prodomain mutations (p.F55S, p.F56S, p.M72T) appeared
to be similar, judged by the effect on the level and enzy-
matic activity of secreted MMP13 protein (Figure 4C),14, 2009
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Figure 3. Concentration and Activity Levels of MMP9 and MMP13 in MAD Patients
(A and B) MMP13 activity is not detectable in the serum (A), and MMP9 activity is reduced in the plasma (B), of patients with dominant
MAD (MMP13 p.F55S, n¼ 3;MMP13 p.M72T, n¼ 3) in comparison to unaffected controls (n¼ 10). SpeciﬁcMMP activity was quantiﬁed
via a ﬂuorogenic peptide substrate cleavage assay. Samples were measured in quadruplicates, and p values were obtained with a two-
tailed Student’s t test for the comparison of means (horizontal line).
(C) Both proMMP13 and proMMP9 are strongly reduced in immunoblot analysis of whole-cell lysates from early-passage ﬁbroblasts of
patient 1 with dominant MAD (MMP13 p.F55S) as compared with an age-matched unaffected control; equal loading is demonstrated by
reprobing with an antibody directed against b-actin.
(D) The plasma of patients with recessive MAD lacks MMP9 activity (MMP9 c.21T>A, p.M1K, n ¼ 2), and heterozygous carriers (n ¼ 2)
show a signiﬁcant reduction in comparison to unaffected controls (n ¼ 10). MMP9 activity was quantiﬁed via a ﬂuorogenic peptide
substrate cleavage assay. Samples were measured in triplicates and p values were obtained with a two-tailed Student’s t test for the
comparison of means (horizontal line).
(E) No lower-sized bands indicative of initiation at downstream start codons are visible in immunoblot analysis of whole-cell lysates from
ﬁbroblasts transfected with minigene constructs bearing the recessive-MAD-associated mutation MMP9 c.21T>A, p.M1K. In wild-type
constructs, proMMP9 is readily detectable with an antibody directed against the carboxy terminus. Transfection efﬁciency was similar,
as monitored by ﬂuorescence microscopy of EGFP expressed from an internal ribosome entry site downstream of MMP9; the promoter
region includes 1644 bp (construct_1) and 762 bp (construct_2) upstream of the MMP9 start codon.arguing against a genotype-phenotype correlation based
on the extent of autoactivation.
Notably, we observed that the dominant-negative effect
of autoactivated MMP13 extended to MMP9 as substrate,
given that no MMP9 was produced by cells cotransfected
with mutant MMP13 and wild-type MMP9 expression
constructs (Figure 5A). Reduced protein levels of mutantThe AmerMMPs were reﬂected by a loss of proteolytic activity for
native collagen and gelatin in conditioned supernatants
of cell lines and ﬁbroblasts (Figure 4C and Figure 5A). In
transfected cells, stability of all disease-associated pro-
MMP13 mutants was restored by additional inactivation
of the catalytic center by site-directed mutagenesis. These
compound transfectants had normal amount and activityican Journal of Human Genetics 85, 168–178, August 14, 2009 173
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Figure 4. Functional Analysis of Disease-Associated MMP13 Mutations in HEK Cells
(A) Schematic diagram of the genomic structure of theMMP13 gene, illustrating the position of MAD-associated mutations and protein
domains. MMP13 encodes a 471 amino acid (aa) preproprotein including a 19 aa signal sequence (S) removed upon secretion, a 84 aa
prodomain (Pro) maintaining latency of the proenzyme, and a 166 aa catalytic domain (Cat) connected by an 11 aa hinge peptide
(H) to the 191 aa hemopexin-like domain (Hpx). The contribution ofMMP13 exons to each protein domain is indicated by color. Within
the catalytic domain, a conserved motif contains three histidine residues that ligate the active site Zn2þ. The prodomain regulates enzy-
matic activity through the molecular interaction between the thiol group of cysteine 77 with the zinc ion in the catalytic center,
modeled in the ribbon diagram of proMMP13 structure. In addition to the zinc-binding amino acids C77 (the ‘‘switching’’ cysteine),
H203, H207, and H213, the atomic structure and relative positions of disease-associated F55 and M72 are shown. For simplicity, only
the Zn2þ of the catalytic core and the central Ca2þ of the hemopexin-like domain are represented, as red and green spheres, respectively.
(B) All dominant-MAD-associated mutations cause a strong reduction of the proMMP13-speciﬁc signal in immunoblot analysis of
whole-cell lysates from human embryonic kidney cells transfected with expression constructs bearing disease-associatedMMP13muta-
tions; there is no apparent difference between the individual dominant-MAD- and SEMDMO-associated mutations. Protein stability is
normal for themutation p.H213N associatedwith recessiveMAD and themissensemutation p.E204A ablating enzymatic activity. Trans-
fection efﬁciency andmRNA stability was similar for all constructs, as analyzed in parallel by quantitative reverse transcriptase-PCR (not
shown); equal protein loading is documented by reprobing the blot with an antibody directed against b-actin.
(C) Collagenase activity for native collagen type II is reduced to background levels by all disease-associatedMMP13missense mutations,
similar to the catalytically inactive mutant p.E204A. Conditioned supernatants of transfected cells were activated with 1 mM APMA for
1 hr. No collagenolysis was detected without activation. Relative collagenase activity was normalized to recombinant MMP13 and total
protein content. Bars represent the mean of triplicates, and error bars indicate the SDM.174 The American Journal of Human Genetics 85, 168–178, August 14, 2009
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Figure 5. Transcatalytic Intracellular Degradation of MMP9 by Autoactivated MMP13
(A) Dominant-MAD-associated MMP13 mutations cause a strong reduction of both MMP13- and MMP9-speciﬁc signals in immunoblot
analysis of whole-cell lysates from human embryonic kidney cells cotransfected with expression constructs bearing disease-associated
MMP13 mutations and wild-type MMP9; loss-of-function mutations do not affect the stability of either protein.
(B) Dominant MMP13 mutations lead to autoactivation and intracellular degradation of both MMP13 and MMP9; MMP stability
is restored by additional inactivation of the catalytic center through the missense mutation p.E204A. Constructs bearing compound
mutations were analyzed by immunoblotting.
(C) Transcatalysis reduces enzymatic activity of secreted MMPs. Dominant MMP13 mutations cause a strong decrease of gelatinase
activity in conditioned supernatants of cotransfected cells, whereas MMP9 activity is not altered by the recessive-MAD-associated
mutant p.H213N. Bars represent the mean of triplicates, and error bars indicate the SDM.
(D) Additional ablation of enzymatic activity in dominant MMP13 mutants by site-directed mutagenesis brings secreted gelatinase
activity back to levels measured in MMP9 wild-type transfectants. Conditioned supernatants were activated with 1 mM APMA for
16 hr. Bars represent the mean of triplicates, and error bars indicate the SDM.of secreted MMP9, proving that in dominant MAD, loss of
both MMP13 and MMP9 protein stability and function
was caused solely by aberrant intracellular activation of
the catalytic domain of MMP13 (Figures 5B and 5D). Secre-
tion of proMMP9 also increased when the mutant MMP13
transcript was speciﬁcally suppressed by siRNA in ﬁbro-
blasts, whereas the level of proMMP9 in control cells re-
mained unchanged (data not shown). Altogether, our
experiments indicate that heterozygosity for critical
MMP13mutations is enough to induce the premature acti-
vation of proMMP13 and that prematurely activated
MMP13 in the endoplasmic reticulum degrades both itselfThe Amer(autocatalytic degradation) and the structurally normal
MMP9 (transcatalytic degradation).
Discussion
MMPs are translated in a prepro form that contains a signal
peptide targeting to the secretorypathwayandaprodomain
maintaining an inactive enzymatic state of proMMPs
within the cell (Figure 4A). The prodomain regulates enzy-
matic activity through a mechanism called ‘‘cysteine
switch,’’ describing the molecular interaction between theican Journal of Human Genetics 85, 168–178, August 14, 2009 175
thiol group of a speciﬁc cysteine in the prodomain with the
zinc ion in the catalytic center27 (Figure 4A and Figure S1).
Enzymatic activity is unleashed only when this interaction
is disrupted, either by modiﬁcation of the free thiol residue
or by cleavage of the prodomain by another proteinase.
Importantly, conformational changes of the proMMP
affecting the thiol-Zn2þ interaction may cause intramolec-
ular autolytic cleavage of the prodomain, thereby irrevers-
ibly activating the catalytic domain.28,29 Amino acid substi-
tutions in proximity of the highly conserved consensus
prodomain sequence PRCxxPD can release the cysteine
switch, resulting in premature intracellular autoactivation
and autodegradation of the enzyme.14,25,28,29 Our observa-
tions in patients and in patient-derived primary cells
conﬁrm the pathogenic relevance of the MMP cysteine-
switch mechanism that had so far been studied only in
heterologous expression systems.14,25 We speculated that
different degrees of MMP13 autoactivation might explain
the apparent phenotypic differences between the pheno-
type of MAD and that of SEMDMO, but this was not sup-
ported by our in vitro data. The metaphyseal features of
both conditions are identical, including the spontaneous
resolution of symptoms, whereas the supposedly discrimi-
nating radiographic changes in the epiphyses and the spine
areminor; in fact, the clinical and radiographic delineation
of SEMDMO was based on a single family, and experts
disagree about the degree of vertebral involvement (J.S.,
S.U., A.S.-F., unpublished data).30 For the time being, we
would tentatively propose that SEMDMO may be a distinct
disorder but could form part of the spectrum of dominant
MAD.
When the data presented here are combined with the
data from mouse experiments, the following pattern
emerges: in spite of partially different expression patterns,
inactivation of either MMP9 or MMP13 (by gene ablation
in mice or by mutations in human recessive MAD) leads
to an identical phenotype of disorganization of the growth
plate, seen as metaphyseal dysplasia on radiographs. The
double knockout (in mice) and the combined deﬁciency
(in human dominant MAD) are only slightly more severe
than the individual enzyme deﬁciencies, suggesting that
these enzymes may act in the same pathway or cascade.
Is a common pathogenetic mechanism responsible for the
similar phenotype? A number of MMPs can cleave the pro-
domain of other MMP zymogens in vitro, and a general
role as activating proprotein convertases was proposed
for the MMPs.28 Notably, active MMP13 effectively con-
verts proMMP9 in vitro,31 and activation of proMMP9
during myoﬁbroblast differentiation requires the presence
of active MMP13.32 In cocultured articular chondrocytes,
MMP13 was identiﬁed as the major upstream proteinase
controlling the conversion and activity of proMMP9
secreted by macrophages, supporting a general role of an
MMP-dependent activation cascade in the pathogenesis
of arthritis.33 Given that our data suggest that MMP13
can target MMP9 intracellularly, it seems likely that
MMP9 is a physiological substrate of MMP13 also in the176 The American Journal of Human Genetics 85, 168–178, Augustextracellular matrix of the growth plate. A sequential,
rather than parallel or divergent, action of MMP13 and
MMP9 might explain the scarcely additive effect of the
combined deﬁciency.
What could be the downstream target(s) of MMP9? In
the growth plate, increased degradation of collagens and
proteoglycans coincides with hypertrophic chondrocyte
differentiation and immediately precedes vascular inva-
sion. A large body of evidence supports that angiogenesis
is the crucial step in bone formation.5,34–37 Whereas
ECM remodelling is essential for vascular invasion to
occur, terminal chondrocyte differentiation, apoptosis,
and matrix remodelling depend on angiogenic factors,
such as VEGFA. MMP9 has been shown to regulate the bio-
availability of VEGFA in the hypertrophic zone of the
growth plate, and blocking Vegfa activity mimics the
Mmp9 knockout phenotype.34,36 Thus, we suggest that
there exists an activation cascade from MMP13 over
MMP9 to VEGFA and that this cascade is disturbed by
isolated loss of either MMP13 or MMP9 function or by
autocatalytic and transcatalytic inactivation of MMP13
and MMP9, leading to reduced release of VEGFA and to
impaired angiogenesis in endochondral ossiﬁcation
(Figure S5).
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